Complaint Counsel's Post Trial Brief - Federal Trade Commission

In the Matter of
)
)
DANIEL CHAER ONE,
a corporation,
)
)
)
)
JAMES FEIJO,
individually, and as an officer of
Daniel Chapter One.
)
)
)
)
I. INTRODUCTION
UNITED STATES OF AMERICA
FEDERA TRAE COMMISSION
Docket No. 9329
PUBLIC DOCUMENT
COMPLAI COUNSEL'S POST-TRI BRIEF
The evidence at tral demonstrated that Respondents Danel Chapter One ("DCO") and
James Feijo violated Sections 5(a) and 12 of
the Federal Trade Commssion Act (the "FTC Act")
when marketing their Bio*Shark, 7 Herb Formula, GDU, and BioMixx products (collectively,
the "DCO Products"). Respondents represented in their adverisements and promotional
materals disseminated on the Interet that the DCO Products were effective in preventing,
treating, or curg cancer or tuors. Respondents preyed upon desperate, sick consumers
"suffer(ing) from any tye of cancer." Respondents touted the DCO Products as "Cancer
solutions" that would "stop tuor growth," "fight() tuor formation," and otherise ''battle()
cancer." Indeed, Respondents admt that they made the following health and disease clais
about the DCO Products:
a. Bio*Shark inbits tuor growth;
b. Bio*Shark is effective in the treatment of cancer;
c. 7 Herb Formula is effective in the treatment or cure of cancer;
1